Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CLPP | Q16740 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776650 | 0.83 | MEN1 (0.50) | SIGMAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5771925 | 0.81 | KMT2A (0.57) | SIGMAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2910250 | 0.81 | MEN1 (0.52) | SIGMAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL2910881 | 0.80 | KMT2A (0.54) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL5777641 | 0.78 | NPC1 (0.49) | MEN1NPC1RAB9AKMT2ACFTR | |
| SCHEMBL28169874 | 0.78 | RAB9A (0.54) | MEN1NPC1RAB9AKMT2ADHFR | |
| SCHEMBL3390108 | 0.76 | HRH3 (0.61) | MEN1NPC1RAB9AKMT2AHRH3 | |
| SCHEMBL2913559 | 0.76 | MEN1 (0.57) | SIGMAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1038680 | 0.75 | KMT2A (0.63) | SIGMAR1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29883119 | 0.75 | KMT2A (0.63) | SIGMAR1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | SIGMAR1 795/4885MEN1 1661/4885NPC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.